[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Manitoba\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":640},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,66,0,25,[9,47,78,101,133,152,175,205,233,267,296,323,347,371,395,414,436,459,483,499,523,546,571,598,618],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100648721","designing-and-implementing-a-safety-net-surveillance-program-for-high-risk-ckd-100648721",false,"NCT07724288","Designing and Implementing a Safety Net Surveillance Program for High Risk CKD","Designing and Implementing a Safety Net Surveillance Program for High Risk CKD (CKD Safety Net)","CKD Safety-Net","Inclusion Criteria:\n\n* Age \\> 18 years old\n* Resident of Manitoba \u002F has Manitoba Health coverage\n* Either:\n* 2 eGFR \\\u003C15 mL\u002Fmin\u002F1.73m2 tests within a 2-year timeframe or\n* A greater than 10% 2-year kidney failure risk (at 2 separate timepoints within a 2-year timeframe) - using the 4-variable or 3-variable 2-year Kidney Failure Risk Equation (KFRE)\n\nExclusion Criteria:\n\n* A previous billing claim from a nephrologist\n* Receiving palliative care within 3 months of randomization\n* Previous history of dialysis and\u002For kidney transplantation","ALL","18 Years",{"count":21,"type":22},972,"ESTIMATED","INTERVENTIONAL",[25],"NA","The objective of this initiative is to develop and evaluate a risk-based, provincial public health screening program for chronic kidney disease (CKD) that provides proactive care for adults at high-risk of kidney failure who have not previously been referred to a nephrologist, through risk stratification, triage, education, and follow-up.\n\nOverall, we aim to demonstrate that an integrated risk-based provincial public health screening program for CKD is feasible, and improves identification of high-risk individuals, subsequently creating a model of care that can be adopted by other jurisdictions.",[28],"Chronic Kidney Diseases",[30,31,32,33],"Chronic Kidney Disease","Kidney Diseases","Access to care","Secondary Prevention","NOT_YET_RECRUITING","2026-08-12",{"date":37,"type":38},"2026-08-17","ACTUAL",{"date":40,"type":22},"2026-08",{"date":42,"type":22},"2028-03",{"name":44,"class":45},"University of Manitoba","OTHER",1,{"id":48,"slug":49,"hasResults":12,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":58,"conditions":59,"keywords":63,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},"100651318","evaluating-in-person-curriculum-for-educating-obstetrical-residents-on-better-caring-for-2-spirit-metis-patients-using-and-ai-assisted-osce-100651318","NCT07760675","Evaluating in Person Curriculum for Educating Obstetrical Residents on Better Caring for 2 Spirit Metis Patients Using and AI Assisted OSCE.","Mawiiyahk Nakatikasho: No One Left Behind: Assessing and Improving Competence in Caring for Two-Spirit Metis Patients Through an AI-Assisted Objective Structured Clinical Examination (OSCE): A Multisite Randomized Controlled Feasibility Trial for Ob\u002FGyn Residents","Inclusion Criteria:\n\n* Current enrollment in an accredited Obstetrics and Gynecology residency program at one of the participating institutions (University of Alberta, University of Manitoba, or University of Saskatchewan). \\* Postgraduate Year 1 through 5 (PGY1-PGY5). \\* Fluency in English to ensure comprehension of AI-based encounters. \\* Willingness and ability to participate fully in both the Academic Half Day and AI-assisted OSCE assessments. \\* Provision of informed consent.\n\nExclusion Criteria:\n\n* Prior participation (within 12 months) in Two-Spirit (2S) Métis-specific or similar cultural safety OSCEs or workshops. \\* Residents not enrolled in participating Ob\u002FGyn residency programs.",true,{"count":56,"type":22},90,[25],"Two-Spirit (2S) Métis individuals often encounter significant barriers and discrimination in healthcare settings. This multisite randomized controlled feasibility trial evaluates a novel artificial intelligence (AI)-assisted Objective Structured Clinical Examination (OSCE) designed to assess and improve Obstetrics and Gynecology (Ob\u002FGyn) residents' competencies in delivering culturally safe, trauma-informed, and identity-affirming care to 2S Métis patients.\n\nUp to 90 Ob\u002FGyn residents across three Canadian academic sites (University of Alberta, University of Manitoba, and University of Saskatchewan) will be randomized 1:1 to complete either a 2S Métis Academic Half Day paired with AI-assisted OSCE evaluation or standard institutional anti-racism training with AI-assisted OSCE evaluation. The primary focus is to evaluate study feasibility (recruitment, retention, and delivery fidelity) and resident performance on clinical communication, trauma-informed care, and cultural humility evaluated using a 2S Métis co-developed scoring rubric.",[60,61,62],"Cultural Safety","Medical Education","Cultural Competency",[64,65,66,67,68,69],"Two-Spirit","Métis","AI","OSCE","Indigenous Health","Obstetrics and Gynecology","2026-08-07",{"date":35,"type":38},{"date":73,"type":22},"2026-09-23",{"date":75,"type":22},"2027-01-30",{"name":44,"class":45},3,{"id":79,"slug":80,"hasResults":12,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":54,"sex":18,"minAge":4,"maxAge":19,"enrollmentInfo":85,"targetDuration":87,"studyType":88,"phases":4,"briefSummary":89,"conditions":90,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":46},"100646295","co-designing-enhanced-models-of-care-for-first-nations-children-at-risk-for-childhood-onset-type-2-diabetes-100646295","NCT07692321","Co-designing Enhanced Models of Care for First Nations Children at Risk for Childhood-onset Type 2 Diabetes","Co-designing Enhanced Models of Care for First Nations Children at Risk for Childhood-onset Type 2 Diabetes: The Next Generation Birth Cohort.","Inclusion Criteria for the breastfeeding program:\n\n* Pregnant women with type 2 diabetes or no diabetes.\n* From self-identified Indigenous heritage (e.g., Cree, Oji-Cree, Métis, Anishinaabe, etc.) residing in the four Anisininew communities in the Island Lake region.\n* Are delivering in Manitoba.\n* Mother\u002FFather and children must be biological family members.\n\nExclusion Criteria from the breastfeeding program:\n\n* Parents or children with type 1 diabetes.\n* Residing outside of Manitoba.\n\nInclusion criteria for the CGM pro",{"count":86,"type":22},600,"4 Years","OBSERVATIONAL","The overall objective: to co-design and implement targeted and timely community led strategies to improve the health of the Next Generation and end the intergenerational impact of T2D in this population.",[91,92],"Type 2 Diabetes","Gestational Diabetes Mellitus (GDM)","2026-07-30",{"date":95,"type":38},"2026-08-03",{"date":97,"type":22},"2026-08-31",{"date":99,"type":22},"2031-03-31",{"name":44,"class":45},{"id":102,"slug":103,"hasResults":12,"nctId":104,"briefTitle":105,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":54,"sex":18,"minAge":19,"maxAge":107,"enrollmentInfo":108,"targetDuration":4,"studyType":23,"phases":110,"briefSummary":111,"conditions":112,"keywords":116,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":46},"100646408","transcutaneous-spinal-electrical-stimulation-to-improve-exercise-function-after-spinal-cord-injury-100646408","NCT07692191","Transcutaneous Spinal Electrical Stimulation to Improve Exercise Function After Spinal Cord Injury.","Inclusion Criteria:\n\n* traumatic or non-traumatic spinal cord injury\n* Spinal cord injury of at least one year duration, C5 or lower, AIS A - D\n* medically stable and healthy enough to engage in and complete exercise requirements\n* willing and able to complete the exercise protocols and testing requirements\n* able to understand and follow written and verbal instructions from study staff\n* able to communicate with study staff about their exercise capabilities and preferences\n\nExclusion Criteria:\n\n* current serious injury (ies) of the upper extremities\n* known cardiovascular disease\n* unsatisfactory results of EKG screening\n* implanted electronic cardiac devices (e.g., pacemaker, defibrillator, etc.)\n* current pressure ulcer(s)\n* morbid obesity\n* known thyroid dysfunction\n* current cancer\n* current uncontrolled high blood pressure\n* uncontrolled epilepsy\n* current deep vein thrombosis\n* ventilator dependency\n* cognitive impairment","70 Years",{"count":109,"type":22},40,[25],"Our overall objective is to decrease the prevalence of multiple sedentary-related diseases that are secondary consequences of spinal cord injury (SCI). SCI affects motor, sensory and autonomic systems and can cause very limited exercise capacity which then leads to very high rates of obesity, metabolic syndrome, type II diabetes and cardiovascular disease.\n\nThis randomized controlled study aims to determine whether and how transcutaneous spinal electrical stimulation (TSES) alters acute (immediate) exercise responses in people living with SCI. Exercise responses will be tested during incremental tests to fatigue, and during steady state tests. Testing will occur over several study visits and results will be compared within each individual as well as between groups (tetraplegia and paraplegia) and to a group of reference controls. A number of outcomes will be monitored, including whole-body metabolic responses using a metabolic cart, muscle responses using EMG sensors and muscle oxygenation using near infrared spectroscopy (NIRS) sensors, time to fatigue, power output, as well as perceptions about fatigue and effort.\n\nThe findings of this study are expected to provide evidence regarding whether and how TSES might improve acute exercise responses in people living with SCI.",[113,114,115],"Spinal Cord Injuries (SCI)","Spinal Cord Injury","Spinal Injury",[117,118,119,120,121,122,123],"exercise","spinal cord injury","sympathetic nervous system","autonomic nervous system","arm ergometry","obesity","cardiovascular disease","RECRUITING","2026-07-02",{"date":127,"type":38},"2026-07-09",{"date":129,"type":38},"2024-06-10",{"date":131,"type":22},"2026-10",{"name":44,"class":45},{"id":134,"slug":135,"hasResults":12,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":139,"eligibilityCriteria":140,"healthyVolunteers":54,"sex":18,"minAge":4,"maxAge":19,"enrollmentInfo":141,"targetDuration":4,"studyType":88,"phases":4,"briefSummary":142,"conditions":143,"keywords":4,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":46},"100410199","the-next-generation-longitudinal-birth-cohort-diabetes-study-100410199","NCT04621396","The Next Generation Longitudinal Birth Cohort Diabetes Study","Genetic and Environmental Influences on Development of Type 2 Diabetes in Childhood: The Next Generation Longitudinal Birth Cohort.","NextGen","Inclusion Criteria:\n\n* Pregnant women with type 2 diabetes, gestational diabetes, or no diabetes.\n* From self-identified Indigenous heritage (e.g., Cree, Oji-Cree, Métis, Anishinaabe, etc.).\n* Are delivering and residing in Manitoba.\n* Mother\u002FFather and children must be biological family members.\n\nExclusion Criteria:\n\n* Mothers or children with type 1 diabetes.\n* Residing outside of Manitoba.",{"count":86,"type":22},"The overall aim of this project is to understand the independent roles of maternal factors, intrauterine exposures, genetic factors, and postnatal environment on the development of obesity and youth-onset type 2 diabetes (T2D) in childhood.",[91,144],"Gestational Diabetes Mellitus","2026-06-30",{"date":125,"type":38},{"date":148,"type":38},"2013-09",{"date":150,"type":22},"2028-12",{"name":44,"class":45},{"id":153,"slug":154,"hasResults":12,"nctId":155,"briefTitle":156,"officialTitle":156,"acronym":157,"eligibilityCriteria":158,"healthyVolunteers":12,"sex":18,"minAge":159,"maxAge":19,"enrollmentInfo":160,"targetDuration":4,"studyType":88,"phases":4,"briefSummary":162,"conditions":163,"keywords":4,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":46},"100271830","improving-renal-complications-in-adolescents-with-type-2-diabetes-through-research-cohort-study-national-icare-study-100271830","NCT02818192","Improving Renal Complications in Adolescents With Type 2 Diabetes Through REsearch Cohort Study (National iCARE Study)","iCARE","Inclusion Criteria:\n\n* All youth with T2D that do not meet exclusion criteria are eligible for the study.\n\nCriteria for Diagnosis of T2D:\n\n1. Diagnosis of diabetes will be made according to the Canadian Diabetes Association criteria. There must be 2 abnormal blood glucose tests on different days OR 1 abnormal blood glucose test + symptoms of diabetes:\n\n   * Fasting plasma glucose of \\> 7.0 mmol\u002FL or\n   * Random glucose \\> 11.1mmol\u002FL or\n   * 2 hour glucose \\> 11.1 mmol\u002FL after a standard oral glucose tolerance test (75g) or\n   * Hemoglobin A1c value ≥ 6.5%\n2. Distinguishing T2D from type 1 diabetes (T1D) will be based on clinical risk factors including:\n\n   * Presence of overweight\u002Fobesity,\n   * Other evidence of insulin resistance (acanthosis nigricans)\n   * Family history of type 2 diabetes (1st degree relative)\n   * Intrauterine exposure to hyperglycemia,\n   * Family heritage from a high-risk ethnic group (Indigenous, Hispanic, South Asian, Asian or African descent)\n   * Absence of diabetes associated auto-antibodies\n   * HNF-1 alpha heterozygote or homozygote\n\nExclusion Criteria:\n\n1. Diabetes secondary to medication use or surgery\n2. Antibodies suggestive of type 1 diabetes\n3. Current treatment with oral steroids or immunosuppressive agents as they may interfere with cortisol assessment and inflammatory markers\n4. Ever cancer\n5. Other chronic illness associated with systemic inflammation (ex. Juvenile rheumatoid arthritis, Crohns disease)\n6. Patient and or caregiver unable or unwilling to provide voluntary informed assent\u002Fconsent","10 Years",{"count":161,"type":22},500,"The overall aim of the project is to elucidate the primary bio-psycho-social (BPS) risk factors for albuminuria in youth with type 2 diabetes (T2D) and the mechanisms by which they cause renal injury. The Study aims include:\n\n1. Characterize the primary BPS risk factors associated with prevalent and progressive albuminuria in youth with T2D.\n2. Determine individual, family and community level factors that influence biological and psychological risk factors and behaviors (adherence) that could be modified to protect against prevalent and progressive albuminuria.\n3. Determine if systemic and renal inflammation is the common pathway through which BPS risk factors lead to albuminuria in youth with T2D.\n\nStudy Hypotheses include:\n\n1. Biological factors (poor glycemic control and systolic ambulatory hypertension), and psychological and social adversity (stress, mental distress and poverty) are significant predictors of prevalent and progressive albuminuria in youth with T2D.\n2. Community and family support will be negatively associated with stress, and a lower risk of both prevalent and progressive albuminuria.\n3. Systemic and renal inflammation is the common pathway through which BPS risk factors lead to albuminuria in youth with T2D.",[91,164,165,166],"Proteinuria","Stress","Nephropathy","2026-06-25",{"date":169,"type":38},"2026-06-29",{"date":171,"type":38},"2017-01",{"date":173,"type":22},"2027-03",{"name":44,"class":45},{"id":176,"slug":177,"hasResults":12,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":181,"eligibilityCriteria":182,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":183,"targetDuration":4,"studyType":23,"phases":185,"briefSummary":187,"conditions":188,"keywords":192,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":46},"100633571","phase-2-evaluation-of-antibiotic-prophylaxis-in-myelodysplastic-syndromes-and-acute-myeloid-leukemia-myelo-canabx-100633571","NCT07528417","Evaluation of Antibiotic Prophylaxis in Myelodysplastic Syndromes and Acute Myeloid Leukemia (MYELO-CAN:ABX)","Evaluation of Antibiotic Prophylaxis Among Outpatients With Myelodysplastic Syndrome and Acute Myeloid Leukemia: a Multicenter Pilot Trial","MYELO-CAN:ABX","Inclusion Criteria:\n\nMaster platform inclusion criteria:\n\n1. Age ≥ 18 years\n2. Diagnosis of myelodysplastic syndrome, myelodysplastic\u002Fmyeloproliferative neoplasm, or acute myeloid leukemia\n\nMYELO-CAN ABX inclusion criteria:\n\n1\\. Initiation of hypomethylating agent-based chemotherapy\n\nExclusion Criteria:\n\nMaster platform exclusion criteria:\n\n1. Participant is deemed unlikely to survive \\>30 days (as determined by clinical team)\n2. Participant unable to provide informed consent\n\nMYELO-CAN ABX exclusion criteria:\n\n1. Fever\u002Finfection within 1 month of chemotherapy initiation\n2. C-difficile infection within 12 months of chemotherapy initiation\n3. Known sensitivity\u002Fallergy to fluoroquinolones\n4. History of tendon disorders related to fluoroquinolone administration\n5. Seizure disorder\n6. Myasthenia gravis\n7. Pregnancy and\u002For breastfeeding",{"count":184,"type":22},75,[186],"PHASE2","Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are serious, life-changing blood cancers. Patients with MDS and AML commonly experience complications related to infection, which affect patient quality-of-life and can sometimes lead to hospitalization or death. The investigators will conduct a randomized controlled trial to evaluate the effectiveness and safety of levofloxacin (antibiotic) in MDS and AML patients to safely reduce the risk of infection. In this study 50% of patients will be randomized (like a flip of a coin) to receive levofloxacin and the other 50% will receive usual care (control). The primary objective of the trial is to demonstrate the feasibility of a pragmatic pilot trial necessary to inform our planned phase 3 trial. Additionally, the investigators will monitor both groups of patients to see if the investigators improve the risk and\u002For severity of infection. Levofloxacin is commonly used in other clinical settings but has not been studied in patients with MDS or AML receiving outpatient chemotherapy (ie, chemotherapy that can be given from clinic, rather than a hospital).",[189,190,191],"Myeldysplastic Syndrome (MDS)","MYELOPROLIFERATIVE DISORDER (P Vera, CMML, ET)","Acute Myeloid Leukemia",[193,194,195,196,191,197],"Levofloxacin","Randomized Controlled Trial","Myelodysplastic Syndrome","Myeloproliferative Neoplasm","Neutropenia","2026-06-24",{"date":169,"type":38},{"date":201,"type":22},"2026-09-01",{"date":203,"type":22},"2028-04-30",{"name":44,"class":45},{"id":206,"slug":207,"hasResults":12,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":211,"eligibilityCriteria":212,"healthyVolunteers":54,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":213,"targetDuration":215,"studyType":88,"phases":4,"briefSummary":216,"conditions":217,"keywords":220,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":230,"leadSponsor":232,"locationsCount":46},"100641351","exploring-the-genetics-of-schizophrenia-in-manitoba-100641351","NCT07656870","Exploring the Genetics of Schizophrenia in Manitoba","Uncovering Schizophrenia Genetics Through Whole Genome Sequencing Across Manitoba","GENES-MB","Inclusion Criteria:\n\n* Individuals aged 18 years and older,\n* Reside in Manitoba,\n* Involved in the EPPIS, STEP, PACT, ACT\u002FFACTT clinics,\n* Clinical diagnosis of schizophrenia using standard DSM-5 criteria,\n* Previously consented and enrolled in the MPR.\n\nExclusion Criteria:\n\n* There are no specific exclusion criteria beyond meeting the inclusion criteria or not providing informed consent.",{"count":214,"type":22},1500,"1 Year","Schizophrenia is a serious mental illness that affects about 1 in 100 Canadians, shortens life expectancy, and places a large burden on individuals, families, and the healthcare system. Genetics are known to play a major role, but current research explains only part of the inherited risk because most studies have looked at only a small portion of the genome and have mainly focused on people outside Canada. This project will create the first large-scale Manitoba-based schizophrenia whole-genome sequencing database by studying 1,500 Manitobans with and without schizophrenia using both short-read and advanced long-read genome sequencing technologies. Researchers will combine genetic data with lifelong provincial health records to better understand rare genetic variants linked to schizophrenia and how genetic differences influence medication response, side effects, hospitalizations, and treatment outcomes. The study aims to fill important gaps in schizophrenia research in Canada, improve understanding of the disorder's biology, and support the development of more personalized and effective treatments for people living with schizophrenia.",[218,219],"Schizophrenia","Healthy (Controls)",[221,222,223,224,225],"schizophrenia","genetics","saliva","genome","sequencing","2026-06-12",{"date":228,"type":38},"2026-06-18",{"date":40,"type":22},{"date":231,"type":22},"2031-04",{"name":44,"class":45},{"id":234,"slug":235,"hasResults":12,"nctId":236,"briefTitle":237,"officialTitle":238,"acronym":239,"eligibilityCriteria":240,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":241,"targetDuration":4,"studyType":88,"phases":4,"briefSummary":243,"conditions":244,"keywords":250,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":258,"lastUpdatePostDateStruct":259,"startDateStruct":261,"completionDateStruct":263,"leadSponsor":265,"locationsCount":266},"100530991","icu-combined-assessment-of-cardio-respiratory-exercise-100530991","NCT06193980","ICU Combined Assessment of Cardio-Respiratory Exercise","Exercise Testing in ICU Survivors to Evaluate ICU-acquired Weakness","ICU-CARE","Inclusion Criteria:\n\n* Patients who have received mechanical ventilation for at least 7 days in the intensive care unit (ICU) and have subsequently been discharged from hospital.\n\nExclusion Criteria:\n\n* Unable to provide consent\n* Trajectory of health expected to be significantly limited in the upcoming 12 months\n* those who self-report that they cannot climb at least one flight of stairs due to limited exercise capacity\n* have significant orthopedic or musculoskeletal impairment affecting mobility\n* have a medical history of neuromuscular disease\n* ongoing respiratory limitations (i.e., supplemental oxygen)\n* significant heart disease (i.e. ejection fraction less than 30%, unstable ischemic heart disease, severe valvular heart disease)\n* a body mass index (BMI) of ≥ 40 kg\u002Fm2 (impacting NIRS signal due to adipose tissue thickness)\n* if participant's primary residence is a significant distance from the participating study site",{"count":242,"type":22},50,"This study aims to investigate how sepsis and critical illness can impair the cardiovascular system and microcirculation in intensive care unit (ICU) patients, which can lead to long-lasting muscle weakness\u002Fdysfunction or ICU-Acquired Weakness (ICU-AW) and exercise limitations.",[245,246,247,248,249],"ICU Acquired Weakness","Sepsis","Shock","Critical Illness","Microcirculation",[251,252,249,253,254,255,256,257],"ICU Survivors","Oxygen Delivery","skeletal muscle","Exercise","near-infrared spectroscopy","cardiopulmonary exercise test","cardiovascular physiology","2026-06-11",{"date":260,"type":38},"2026-06-15",{"date":262,"type":38},"2023-12-15",{"date":264,"type":22},"2029-12",{"name":44,"class":45},2,{"id":268,"slug":269,"hasResults":12,"nctId":270,"briefTitle":271,"officialTitle":272,"acronym":273,"eligibilityCriteria":274,"healthyVolunteers":12,"sex":18,"minAge":275,"maxAge":276,"enrollmentInfo":277,"targetDuration":4,"studyType":23,"phases":278,"briefSummary":279,"conditions":280,"keywords":282,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":290,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":295,"locationsCount":4},"100594768","phase-2-cannabinoids-for-drug-resistant-epilepsy-dre-in-adults-and-children-100594768","NCT07023744","CANnabinoids for Drug Resistant Epilepsy (DRE) in Adults and Children","A Triple-Blind, Placebo-Controlled, Randomized Clinical Trial of CANnabinoids for Drug Resistant Epilepsy in Adults and Children","CAN-DRE","Inclusion Criteria:\n\n1. Ages 24 months to 55 years old at the time of enrollment\n2. Diagnosed with DRE: not achieved seizure freedom, with adequate trials of 2 antiseizure medications 29\n3. Medical history of 4 + clinically recognizable seizures (any type with clusters counted as a single event) per month\n4. Have a negative pregnancy test at screening for patients who have experienced menarche\n5. Agree to abstain from driving and recreational cannabis use throughout the study\n\nExclusion Criteria:\n\n1. Diagnosis of psychogenic non-epileptic seizure\n2. Recent (\\\u003C30 days) change in anticonvulsant therapies including anticonvulsant medications, or settings on vagal nerve stimulator\n3. Ketogenic diet started within 6 months (participants stable on the ketogenic diet for more than 6 months are eligible to participate)\n4. Vagal nerve stimulator implanted and activated within 12 months\n5. Concomitant regular use of narcotics (except in emergencies and physician supervised)\n6. Initiation or dosage change of oral or injected steroids within 3 months\n7. Allergy or intolerance to compounds in trial preparations\n8. DRE secondary to progressive neurological disease\n9. Clinically significant cardiac, renal or hepatic disease (as assessed by site investigator); elevated liver enzymes (GGT and\u002For AST and\u002For ALT) or lipase \\>3 times upper limit, adjusted for age\n10. History of psychotic disorders\n11. Uncontrolled (in the perspective of the qualified investigator) medical conditions including substance use disorders\n12. History or concurrent cannabis use disorder\n13. Unwilling or unable to use highly effective methods of contraception throughout the study period and three months post-trial, where applicable","24 Months","55 Years",{"count":56,"type":22},[186],"Epilepsy is a neurological disorder affecting more than 50 million people globally, including more than 260,000 Canadians. Cannabidiol (CBD) reduces seizure frequency and improves quality of life for adults and children with Drug Resistant Epilepsy (DRE). Several uncontrolled, small, open label studies reported that CBD-enriched Cannabis Herbal Extract (CHE) resulted in a reduction of seizure frequency, but we lack critical information on efficacy, comparative effectiveness and dosing of CBD and ∆9-tetrahydrocannabinol (THC) in children and adults with DRE. CAN-DRE is an early phase, triple-blind, placebo-controlled, randomized clinical trial to answer the questions of if cannabinoids work to reduce seizures in children and adults (24 months to 55 years) with DRE and if CBD works better in an isolate or in a CBD-enriched Cannabis Herbal Extract. The primary outcome of CAN-DRE is reported monthly seizure count from baseline to maintenance phase.",[281],"Drug Resistant Epilepsy",[283,284,285,286,287,288],"adult and children","cannabis","DRE","CBD-isolate","CBD-enriched Cannabis Herbal Extract (CHE)","cannabidiol","2026-06-09",{"date":258,"type":38},{"date":292,"type":22},"2026-07-27",{"date":294,"type":22},"2028-03-31",{"name":44,"class":45},{"id":297,"slug":298,"hasResults":12,"nctId":299,"briefTitle":300,"officialTitle":301,"acronym":302,"eligibilityCriteria":303,"healthyVolunteers":12,"sex":18,"minAge":87,"maxAge":19,"enrollmentInfo":304,"targetDuration":4,"studyType":23,"phases":306,"briefSummary":308,"conditions":309,"keywords":312,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":317,"startDateStruct":318,"completionDateStruct":320,"leadSponsor":322,"locationsCount":77},"100497253","phase-1-cannabinoids-in-pediatric-oncology-100497253","NCT05754840","CANnabinoids in Pediatric ONCology","A Randomized, Double-Blind Tolerability Trial of Cannabinoids for Symptom Management in Children With Cancer: the CAN-PONC Trial","CAN-PONC","Inclusion Criteria:\n\n1. Ages 4-17 years old at the time of enrollment\n2. Diagnosed with relapsed or refractory solid or hematologic malignancy including brain tumours\n3. Currently receiving active cancer treatment or supportive and palliative care\n4. Estimated survival of at least 4 months at the time of enrollment\n\nExclusion Criteria:\n\n1. History of cardiovascular disease, severe hepatic or renal impairment defined by alanine transaminase (ALT)\u002F aspartate aminotransferase (AST) more than 5x upper limit of normal (ULN), creatinine more than 5x ULN or glomerular filtration rate (GFR less than) \\\u003C60 mL\u002Fmin\u002F1.73 m273m2, unstable\u002Funmanaged arrhythmias, uncontrolled hypertension with blood pressure above 99th centile for age or history of myocardial infarction\n2. Nabilone or other cannabis-based products use (including for recreational purposes) within the past 2 weeks or planned nabilone use for the duration of their enrollment in the trial. Current use\u002Fcontinued use of recreational cannabis, or not willing to abstain from recreational cannabis use during the trial\n3. Anyone who is pregnant or breast\u002Fchest-feeding throughout the duration of the study or has the intention to become pregnant within 3 months of study completion\n4. Participation in other clinical trials that prohibit the concurrent use of cannabis\n5. Children with a personal or family history of schizophrenia or psychotic disorders, substance use disorder or allergy to cannabinoids or cannabis\n6. Unwilling or unable to use effective form of contraception and refrain from driving motorized vehicles (cars, motorcycles, boats, etc.) throughout the study period\n7. Anyone who is currently receiving cell therapies or immune checkpoint inhibitors",{"count":305,"type":22},60,[307,186],"PHASE1","CANnabinoids in Pediatric ONCology is a randomized, double blind, adaptive clinical trial looking at the tolerability of cannabinoids in children with cancer across 3 Canadian children's hospitals.",[310,311],"Childhood Cancer","Cancer",[313,314,315,316,284],"cannabinoids","CBD","THC","pediatrics",{"date":258,"type":38},{"date":319,"type":38},"2025-07-18",{"date":321,"type":22},"2026-12-31",{"name":44,"class":45},{"id":324,"slug":325,"hasResults":12,"nctId":326,"briefTitle":327,"officialTitle":328,"acronym":4,"eligibilityCriteria":329,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":330,"targetDuration":4,"studyType":23,"phases":332,"briefSummary":333,"conditions":334,"keywords":336,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":340,"lastUpdatePostDateStruct":341,"startDateStruct":343,"completionDateStruct":344,"leadSponsor":346,"locationsCount":4},"100638071","vr-assisted-exercise-for-symptom-management-and-rehabilitation-in-interstitial-lung-disease-100638071","NCT07628725","VR-Assisted Exercise for Symptom Management and Rehabilitation in Interstitial Lung Disease","Virtual Reality-Assisted Breathing Exercises to Support Symptom Management and Rehabilitation in Interstitial Lung Diseases","Inclusion Criteria:\n\n* ≥ 18 years old\n* able to understand English\n* diagnosed with Interstitial Lung Disease (ILD)\n\nExclusion Criteria:\n\n* experiencing acute exacerbation of their condition\n* being unable to provide informed consent\n* being unable to participate in a VR-based intervention",{"count":331,"type":22},32,[25],"This project aims to create and improve a VR-based breathing exercise program for patients with interstitial lung diseases (ILDs). It involves three phases: (1) developing an interactive VR application with guided breathing exercises and real-time biofeedback tailored for ILD patients, (2) testing its feasibility by evaluating usability and acceptability, and (3) refining the intervention based on feedback from the feasibility study.",[335],"Interstitial Lung Disease (ILD)",[337,338,339],"Interstitial Lung Disease","Telerehabilitation","VR-based","2026-06-02",{"date":342,"type":38},"2026-06-05",{"date":260,"type":22},{"date":345,"type":22},"2026-12-15",{"name":44,"class":45},{"id":348,"slug":349,"hasResults":12,"nctId":350,"briefTitle":351,"officialTitle":352,"acronym":353,"eligibilityCriteria":354,"healthyVolunteers":12,"sex":18,"minAge":355,"maxAge":356,"enrollmentInfo":357,"targetDuration":4,"studyType":23,"phases":358,"briefSummary":359,"conditions":360,"keywords":4,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":363,"lastUpdatePostDateStruct":364,"startDateStruct":366,"completionDateStruct":368,"leadSponsor":370,"locationsCount":266},"100538911","type-1-diabetes-exercise-and-mentoring-trial-100538911","NCT06296992","Type 1 Diabetes, Exercise and Mentoring Trial","Type 1 Diabetes, Exercise and Mentoring (TEAM) Trial: A Randomized Controlled Pilot Trial Using Peer Mentorship to Increase Physical Activity and Quality of Life in Adolescents With Type 1 Diabetes","TEAM","Inclusion Criteria:\n\n* want to increase their daily PA\n* currently use a continuous glucose monitor (CGM)\n\nExclusion Criteria:\n\n* were diagnosed with T1D within 12 months of randomization\n* have diabetes secondary to medications or surgery\n* have cancer\n* evidence of drug\u002Falcohol abuse\n* have an eating disorder\n* an orthopedic injury or illness that would limit their ability to engage in daily PA\n* a suicide attempt in the previous 12 months\n* are pregnant","13 Years","17 Years",{"count":305,"type":22},[25],"The proposed study aims to improve the psychosocial health of adolescents living with type 1 diabetes (T1D). The study will generate knowledge and support knowledge mobilization about the effectiveness of a novel model of care for psychosocial health and self-management for adolescents living with type 1 diabetes (T1D). The novel model of care is the recruitment and training if young adult mentors to deliver a behavioural intervention that empowers adolescents with T1D to increase daily physical activity. The study will also advance the development and implementation of this peer mentoring model to improve the psychosocial health of adolescents with T1D.",[361,362],"Type 1 Diabetes","Physical Activity","2026-05-27",{"date":365,"type":38},"2026-06-01",{"date":367,"type":38},"2025-02-01",{"date":369,"type":22},"2027-05",{"name":44,"class":45},{"id":372,"slug":373,"hasResults":12,"nctId":374,"briefTitle":375,"officialTitle":376,"acronym":4,"eligibilityCriteria":377,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":378,"targetDuration":4,"studyType":23,"phases":379,"briefSummary":380,"conditions":381,"keywords":383,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":387,"lastUpdatePostDateStruct":388,"startDateStruct":390,"completionDateStruct":392,"leadSponsor":394,"locationsCount":46},"100439337","phase-1-a-between-patient-study-of-plurogel-compared-to-standard-topical-dressing-in-burn-injuries-100439337","NCT05000983","A Between Patient Study of Plurogel® Compared to Standard Topical Dressing in Burn Injuries","A Between Patient, Pilot Randomized Controlled Study of Plurogel® Compared to Standard Topical Dressing in Burn Injuries","Inclusion Criteria:\n\n* Persons with partial thickness face burns or unilateral limb burn injuries requiring admission.\n\nExclusion Criteria:\n\n* Total burn surface area (TBSA) \\>30%.\n* Burn depth full thickness or deeper on initial assessment.\n* Prior excision at another healthcare centre.\n* Patients with pre-existing malnutrition\n* Electrical, chemical or other unusual burn etiologies",{"count":7,"type":22},[307,186],"Burn injuries can result in long term physical and mental sequelae, not only from the scarring but also the painful dressings. The standard of care today remains use of antibiotic topical dressings while awaiting demarcation of the burn depth, with surgical excision and grafting for deep partial thickness and full thickness areas. Demarcation can be appreciated on admission for full thickness burns but is often a prolonged process that can last weeks. The clinical evaluation of the depth of the burn is a complex decision that often is made more challenging by the presence of the proteinaceous pseudoeschar and the coagulated dermis itself. Surgical debridement is relatively 'coarse' and by its very nature requires removal of a thin layer of viable tissue to reach the level that is vascularized enough to support a skin graft. There has been growing interest in the use of adjuncts to reduce the amount tissue debrided and potentially reduce the need for surgery itself. Operatively, there have been some reports that use of hydro-dissection devices (Versajet™) may allow a more controlled debridement, resulting in less viable tissue being sacrificed. There is also a growing experience with enzymatic debridement, especially with Bromolein, derived from Pineapple (NexoBrid®). Neither of these have been shown to definitively improve care in randomized controlled trials, (RCTs) and there is suggestion that in some settings may actually cause harm.",[382],"Burns",[384,385,386],"burn","wound","debridement","2026-05-11",{"date":389,"type":38},"2026-05-14",{"date":391,"type":38},"2021-10-20",{"date":393,"type":22},"2029-12-31",{"name":44,"class":45},{"id":396,"slug":397,"hasResults":12,"nctId":398,"briefTitle":399,"officialTitle":400,"acronym":4,"eligibilityCriteria":401,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":402,"targetDuration":4,"studyType":23,"phases":404,"briefSummary":380,"conditions":405,"keywords":406,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":387,"lastUpdatePostDateStruct":408,"startDateStruct":409,"completionDateStruct":411,"leadSponsor":413,"locationsCount":46},"100431113","phase-1-a-study-of-plurogel-compared-to-standard-topical-dressing-in-burn-injuries-100431113","NCT04893863","A Study of Plurogel® Compared to Standard Topical Dressing in Burn Injuries","A Within Patient, Pilot Randomized Controlled Study of Plurogel® Compared to Standard Topical Dressing in Burn Injuries","Inclusion Criteria:\n\n* Persons with bilateral limb partial thickness burn injuries of similar depth requiring admission\n\nExclusion Criteria:\n\n* Total body surface area (TBSA) of burn \\>30%.\n* Burn depth full thickness or deeper on initial assessment.\n* Prior excision at another healthcare centre.\n* Patients with pre-existing malnutrition\n* Electrical, chemical or other unusual burn etiologies",{"count":403,"type":22},20,[307,186],[382],[384,385,407,386],"dressing",{"date":389,"type":38},{"date":410,"type":38},"2021-10-01",{"date":412,"type":22},"2029-06-01",{"name":44,"class":45},{"id":415,"slug":416,"hasResults":12,"nctId":417,"briefTitle":418,"officialTitle":419,"acronym":4,"eligibilityCriteria":420,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":421,"targetDuration":4,"studyType":23,"phases":423,"briefSummary":425,"conditions":426,"keywords":428,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":387,"lastUpdatePostDateStruct":430,"startDateStruct":431,"completionDateStruct":433,"leadSponsor":435,"locationsCount":46},"100339160","early-phase-1-a-pilot-trial-of-disposable-nitrous-oxide-canisters-in-providing-pain-control-during-burn-dressing-changes-100339160","NCT03695887","A Pilot Trial of Disposable Nitrous Oxide Canisters in Providing Pain Control During Burn Dressing Changes","A Pilot Randomized Controlled Crossover Trial of the Effectiveness of Disposable Nitrous Oxide Canisters in Providing Improved Pain Control During Burn Dressing Changes.","Inclusion criteria\n\n* adult burn patients admitted to the Health Sciences Centre\n* total body surface area burned of 5-20%\n\nExclusion criteria\n\n* admitted to intensive care unit\n* unable to participate in the measurement outcomes (sedated, cognitively impaired, unable to understand English or visually impaired)\n* medical condition that precludes using nitrous oxide (respiratory disease and significant cardiovascular disease 5).\n* pregnant\n* physically unable to hold the canister\n* \\\u003C90% SaO2 on room air\n* face burn\n* pre-injury narcotics (relative exclusion)\n* use of IV ketamine\n* pre-existing lung injury",{"count":422,"type":22},30,[424],"EARLY_PHASE1","Improvements in burn care have resulted in increased survival. Despite these improved outcomes one of the leading challenges of burn care remains providing adequate analgesia during routine wound care and dressing changes. The traditional use of narcotics is challenging as the therapeutic window between analgesia and suppression of breathing becomes narrow with the intense pain and high doses of narcotics needed for dressing changes.",[382,427],"Pain, Acute",[429],"burns, pain, dressing change, nitrous oxide",{"date":389,"type":38},{"date":432,"type":38},"2019-10-01",{"date":434,"type":22},"2029-12-01",{"name":44,"class":45},{"id":437,"slug":438,"hasResults":12,"nctId":439,"briefTitle":440,"officialTitle":441,"acronym":4,"eligibilityCriteria":442,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":443,"enrollmentInfo":444,"targetDuration":4,"studyType":23,"phases":446,"briefSummary":447,"conditions":448,"keywords":450,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":387,"lastUpdatePostDateStruct":453,"startDateStruct":454,"completionDateStruct":456,"leadSponsor":458,"locationsCount":46},"100188653","phase-1-phenylephrine-tumescence-for-hemostasis-in-surgery-for-burn-injury-100188653","NCT01731444","Phenylephrine Tumescence for Hemostasis in Surgery for Burn Injury","Phenylephrine Tumescence for Hemostasis in Surgery for Burn Injury - A Randomized Control Trial","Inclusion Criteria\n\na) Burn injury requiring debridement and grafting between 5-30% TBSA\n\nExclusion Criteria\n\n1. Head and neck, hand, foot, or genital burns\n2. On anticoagulants (except NSAIDs)\n3. On monoamine oxidase inhibitor or tricyclic antidepressant\n4. Coronary or peripheral vascular disease\n5. History of arrhythmias\n6. On a Beta-blocker\n7. History of vascular abnormality\n8. Hypertension","75 Years",{"count":445,"type":22},24,[307],"The standard of care for treatment of burn injury is to inject a solution of epinephrine under the skin of the injured site in order to reduce blood loss during skin grafting. This solution of epinephrine has been shown to have effects on the body outside the donor site. Some people have increases in heart rate and blood pressure. We will study the effect of a phenylephrine solution in place of an epinephrine solution to control blood loss. We think that phenylephrine will help decrease blood loss and not change blood pressure or heart rate.\n\nThe injured area will be injected under the skin and a skin graft will be taken in the same way as we usually do. The only change will be the use of phenylephrine in the solution instead of epinephrine.\n\nOur goal is to find whether or not phenylephrine or epinephrine solution results in a reduction of blood loss without affecting the rest of the body.",[449],"Blood Loss, Surgical",[451,384,452],"blood loss","hemostasis",{"date":389,"type":38},{"date":455,"type":38},"2014-12-01",{"date":457,"type":22},"2028-12-31",{"name":44,"class":45},{"id":460,"slug":461,"hasResults":12,"nctId":462,"briefTitle":463,"officialTitle":463,"acronym":4,"eligibilityCriteria":464,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":465,"enrollmentInfo":466,"targetDuration":4,"studyType":23,"phases":468,"briefSummary":469,"conditions":470,"keywords":472,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":387,"lastUpdatePostDateStruct":477,"startDateStruct":478,"completionDateStruct":480,"leadSponsor":482,"locationsCount":46},"100180182","the-role-of-fractional-vascular-laser-therapy-in-the-management-of-burn-scars-100180182","NCT01619917","The Role of Fractional Vascular Laser Therapy in the Management of Burn Scars","Inclusion Criteria:\n\n* living in Winnipeg\n* burn scar 6-12 months old\n* Fitzpatrick skin type I-III\n* thermal burn scar on trunk or extremities\n\nExclusion Criteria:\n\n* open wound","60 Years",{"count":467,"type":22},6,[25],"While the literature tends to support the use of laser therapy in the management of burn scars, there is a definite lack of appropriately powered, randomized controlled trials. Laser therapy can be quite expensive when compared to other treatment modalities for burn scars, and while promising, its true usefulness has yet to be conclusively demonstrated. For this reason, our assessing the effects of fractional vascular lasers on burn scars. It has been hypothesized that the fractional vascular lasers work on mature scars to decrease scar formation, and the fractional laser works on scar that is quiescent to promote remodelling. The retexturing\u002F resurfacing of the laser theoretically can decrease the visibility of the mesh pattern created by meshed split thickness skin graft).\n\nObjective:\n\nTo determine the benefit of fractional vascular laser treatment in improving burn scar height, texture, vascularity and pliability in late burn scars.",[471],"Burn Scar",[384,473,474,475,476],"scar","laser","fractional","vascular",{"date":389,"type":38},{"date":479,"type":4},"2012-11-01",{"date":481,"type":22},"2028-07-01",{"name":44,"class":45},{"id":484,"slug":485,"hasResults":12,"nctId":486,"briefTitle":487,"officialTitle":487,"acronym":4,"eligibilityCriteria":488,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":465,"enrollmentInfo":489,"targetDuration":4,"studyType":23,"phases":490,"briefSummary":491,"conditions":492,"keywords":493,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":387,"lastUpdatePostDateStruct":494,"startDateStruct":495,"completionDateStruct":496,"leadSponsor":498,"locationsCount":46},"100170131","the-role-of-pulsed-dye-laser-therapy-in-the-management-of-burn-scars-100170131","NCT01488240","The Role of Pulsed Dye Laser Therapy in the Management of Burn Scars","Inclusion Criteria:\n\n* burn scar\n* living in Winnipeg\n* scar age one to 6 months\n* Fitzpatrick I-III skin type\n\nExclusion Criteria:\n\n* open wound\n* active infection\n* previous scar treatment with steroid injection or interferon\n* established disposition towards keloid scarring",{"count":467,"type":22},[25],"The purpose of this study is to determine the effects (good or bad) of pulsed dye laser treatment in burn scar height, texture, redness and pliability in acute burn injury.",[471],[384,473,474],{"date":389,"type":38},{"date":479,"type":4},{"date":497,"type":22},"2028-06-01",{"name":44,"class":45},{"id":500,"slug":501,"hasResults":12,"nctId":502,"briefTitle":503,"officialTitle":503,"acronym":4,"eligibilityCriteria":504,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":505,"targetDuration":4,"studyType":23,"phases":506,"briefSummary":507,"conditions":508,"keywords":510,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":516,"lastUpdatePostDateStruct":517,"startDateStruct":519,"completionDateStruct":521,"leadSponsor":522,"locationsCount":46},"100621122","feasibility-of-a-multimodal-virtual-reality-intervention-to-reduce-preoperative-anxiety-in-cancer-surgery-patients-100621122","NCT07366515","Feasibility of a Multimodal Virtual Reality Intervention to Reduce Preoperative Anxiety in Cancer Surgery Patients","Patients will be deemed eligible for inclusion if they: (a) are 18 years of age or older; (b) are able to speak and read English; (c) have received a cancer diagnosis; and (d) are scheduled, or in the process of being scheduled to undergo oncological surgery under general anesthesia at the Health Sciences Centre Winnipeg. Patients will be deemed ineligible if they are unable to provide informed consent (e.g., due to cognitive impairment) or if they have any visual, auditory and\u002For motor impairments that would preclude effective participation in the Virtual Reality intervention.",{"count":403,"type":22},[25],"The goal of this study is to assess the feasibility of an expanded virtual reality (VR) intervention designed to help prepare patients for cancer surgery. This study will: (1) assess the investigator's ability to recruit, retain, and engage participants, (2) evaluate how acceptable participants find the intervention through their feedback on its individual components. The investigators will also explore whether baseline anxiety levels or psychiatric history predict responses to the intervention, as well as look for any changes in perioperative anxiety and monitoring for any adverse effects associated with the intervention. This study will also investigate engagement of providing participants with a first-person VR session recordings to determine utility and whether post-session access is perceived as beneficial. Finally, preliminary pilot outcomes will examine whether increased engagement in the VR results in reductions in anxiety on the day of surgery.",[509],"Oncologic Surgery",[511,512,513,514,515],"virtual reality","oncological surgery","feasibility","perioperative mental health","preoperative anxiety and distress","2026-04-28",{"date":518,"type":38},"2026-05-05",{"date":520,"type":38},"2026-04-22",{"date":145,"type":22},{"name":44,"class":45},{"id":524,"slug":525,"hasResults":12,"nctId":526,"briefTitle":527,"officialTitle":528,"acronym":4,"eligibilityCriteria":529,"healthyVolunteers":54,"sex":530,"minAge":19,"maxAge":4,"enrollmentInfo":531,"targetDuration":4,"studyType":23,"phases":532,"briefSummary":533,"conditions":534,"keywords":539,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":516,"lastUpdatePostDateStruct":541,"startDateStruct":542,"completionDateStruct":544,"leadSponsor":545,"locationsCount":46},"100597183","perioperative-virtual-reality-intervention-for-pain-and-anxiety-during-vasectomies-100597183","NCT07055178","Perioperative Virtual Reality Intervention for Pain and Anxiety During Vasectomies","A Perioperative Virtual Reality Intervention for Pain and Anxiety Management During Vasectomies: A Randomized Controlled Trial","Inclusion Criteria:\n\n* 18 years of age or older.\n* Can speak and read English.\n* Have elected for a vasectomy.\n* Are scheduled to undergo their vasectomy under local anesthesia at the Men's Health Clinic\n\nExclusion Criteria:\n\n* Those who are not competent to provide informed consent (e.g., due to cognitive impairment).\n* Those who are unable to participate in a VR intervention (e.g., due to visual or auditory impairment).","MALE",{"count":56,"type":22},[25],"The goal of this clinical trial is to learn if a virtual reality (VR) program (TRIPP) can reduce pain, anxiety, and distress in adult men (aged 18+) undergoing a vasectomy under local anesthesia. The main questions it aims to answer are:\n\n* Does using VR during a vasectomy lower patients' pain during the procedure compared to standard care?\n* Does VR reduce anxiety and distress compared to standard care?\n* Are patients more satisfied with their experience when using VR compared to standard care?\n\nResearchers will compare two groups:\n\n* VR group: Patients will use a VR headset with a guided meditation program (TRIPP) during their vasectomy.\n* Control group: Patients will receive standard care (no VR).\n\nParticipants will:\n\n* Be randomly assigned to either the VR group or control group.\n* Complete brief questionnaires before, during, and after the procedure (about 15-20 minutes each time).\n* (VR group only) Use a VR headset during the procedure and provide optional feedback about the experience.\n\nWhy is this important? Vasectomies are typically done with local anesthesia (pain relief), but many patients still feel anxiety or discomfort. VR may help distract and relax patients, improving their experience. This study will help health professionals understand if VR could be a useful option for future patients.",[535,536,537,538],"Vasectomy","Pain","Anxiety","Virtual Reality",[538,540,535],"TRIPP",{"date":518,"type":38},{"date":543,"type":38},"2025-07-02",{"date":40,"type":22},{"name":44,"class":45},{"id":547,"slug":548,"hasResults":12,"nctId":549,"briefTitle":550,"officialTitle":551,"acronym":4,"eligibilityCriteria":552,"healthyVolunteers":54,"sex":18,"minAge":553,"maxAge":554,"enrollmentInfo":555,"targetDuration":4,"studyType":23,"phases":556,"briefSummary":557,"conditions":558,"keywords":561,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":516,"lastUpdatePostDateStruct":565,"startDateStruct":566,"completionDateStruct":568,"leadSponsor":570,"locationsCount":46},"100540637","technology-in-play-for-children-with-physical-disabilities-the-dice-model-of-play-100540637","NCT06319430","Technology in Play for Children With Physical Disabilities: the Dice Model of Play","The Role of Technology in Facilitating Play for Children With Physical Disabilities: Development of the Dice Model of Play","Inclusion Criteria:\n\n* Having a disability or typically developed\n* Between 3 to 9 years old\n* Speaking and understanding English or Persian\n* Living in Winnipeg\n\nExclusion Criteria:\n\n* Not receiving play therapy within the last three months","3 Years","9 Years",{"count":403,"type":22},[25],"Play is an important activity for children. Almost all children play, but what is play? It is not easy to define play. In the past, people believed that children played to burn their energy. Now, it is known that play is important for children's growth. Some kids with disabilities cannot play. Many experts use play to teach children specific skills. People often forget that play is a child's right. It is important to help all children play. The first step is to define play and find what features are important in helping a child with a disability play.\n\nThere are some models of play. But they are not complete. They do not look at play as a whole. Some models are just about playfulness, and some are about playing with others. Having a model that defines play helps researchers and clinicians think about play and the different parts of it. Then, when a child cannot play, experts can fix the part that is not working. Investigators want to introduce a model of play in this project. Investigators want to edit and complete it in three steps. First, Investigators will ask parents and children with disabilities about things that help or do not help them play; then, investigators will give Lego robots to children that they will build with help and play with them for a few weeks. And at the end, investigators will ask therapists and other experts about our model of play. This model will be edited during the study.",[559,560],"Disability Physical","Disabilities Mental",[562,563,564],"play and playthings","Assistive technology","Pediatric ALL",{"date":518,"type":38},{"date":567,"type":38},"2025-02-06",{"date":569,"type":22},"2026-05-28",{"name":44,"class":45},{"id":572,"slug":573,"hasResults":12,"nctId":574,"briefTitle":575,"officialTitle":575,"acronym":4,"eligibilityCriteria":576,"healthyVolunteers":12,"sex":18,"minAge":577,"maxAge":356,"enrollmentInfo":578,"targetDuration":4,"studyType":23,"phases":579,"briefSummary":580,"conditions":581,"keywords":588,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":516,"lastUpdatePostDateStruct":592,"startDateStruct":593,"completionDateStruct":595,"leadSponsor":597,"locationsCount":46},"100514681","level-up-adaptive-gaming-for-children-with-upper-limb-differences-100514681","NCT05981664","Level Up! Adaptive Gaming for Children With Upper Limb Differences","Inclusion Criteria:\n\n* between the age of 7 and 17 years\n* has a unilateral limb difference\n* limb difference may be from any cause (congenital difference, traumatic loss, etc.)\n* limb difference may be of any level (partial hand, wrist disarticulation, transradial, elbow disarticulation, transhumeral, shoulder disarticulation)\n* ability to communicate in English\n* cognitive ability to follow instructions\n* eligible participants will be included regardless of history of prosthesis use\n* lives locally (Winnipeg) or willing and able to travel to Rehabilitation Centre for Children for 2 appointments\n\nExclusion Criteria:\n\n* less than 7 or greater than 17 years of age\n* bilateral or no limb upper limb difference\n* inability to communicate in English\n* cognitive inability to follow instructions\n* unable or unwilling to attend 2 appointments at Rehabilitation Centre for Children","7 Years",{"count":403,"type":22},[25],"The goal of this clinical trial is to test a new one-handed video game controller adapter to determine if it helps improve how video games are played and enjoyed in children with an upper limb difference on one side. The main questions it aims to answer are:\n\n* Is performance improved while playing video games with the adapter?\n* Is user satisfaction or enjoyment improved while playing video games with the adapter?\n\nParticipants will:\n\n* Answer questions about their limb difference and other demographics\n* Be interviewed about their current and past video game playing experiences\n* Learn how to use the adapter and have their performance with it evaluated\n* Take the adapter home to use for 1 week, and be asked to record their experiences\n* Have their performance with the adapter re-evaluated after a week of practice\n* Be interviewed about their experience with the adapter",[582,583,584,585,586,587],"Upper Limb Amputation at the Wrist","Pediatric","Upper Limb Amputation","Upper Limb Amputation at the Hand","Amniotic Band Syndrome","Upper Limb Amputation Below Elbow (Injury)",[589,590,591],"pediatric","upper limb difference","one handed gaming",{"date":518,"type":38},{"date":594,"type":38},"2024-01-01",{"date":596,"type":22},"2027-06",{"name":44,"class":45},{"id":599,"slug":600,"hasResults":12,"nctId":601,"briefTitle":602,"officialTitle":603,"acronym":4,"eligibilityCriteria":604,"healthyVolunteers":54,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":605,"targetDuration":4,"studyType":23,"phases":607,"briefSummary":608,"conditions":609,"keywords":4,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":611,"lastUpdatePostDateStruct":612,"startDateStruct":614,"completionDateStruct":616,"leadSponsor":617,"locationsCount":46},"100512984","hd-tdcs-to-modulate-connectivity-100512984","NCT05959551","HD-tDCS to Modulate Connectivity","Modulating Functional Brain Connectivity Using High Definition Transcranial Direct Current Stimulation (HD-tDCS)","Inclusion Criteria:\n\n\\- All other than excluded.\n\nExclusion Criteria:\n\n* History or susceptibility to any neurological or psychiatric diseases, particularly seizures\n* abnormal MRI\n* metal implants or a cardiac pacemaker\n* pregnant or breastfeeding women",{"count":606,"type":22},100,[25],"The purpose of the proposed study is to broaden our understanding on the neural effects of High Definition Transcranial Direct Current Stimulation (HD-tDCS) so that its clinical effects can be further improved.",[610],"Electricity; Effects","2026-04-27",{"date":613,"type":38},"2026-05-01",{"date":615,"type":38},"2023-07-01",{"date":97,"type":22},{"name":44,"class":45},{"id":619,"slug":620,"hasResults":12,"nctId":621,"briefTitle":622,"officialTitle":623,"acronym":624,"eligibilityCriteria":625,"healthyVolunteers":12,"sex":18,"minAge":626,"maxAge":4,"enrollmentInfo":627,"targetDuration":4,"studyType":23,"phases":629,"briefSummary":630,"conditions":631,"keywords":4,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":611,"lastUpdatePostDateStruct":634,"startDateStruct":635,"completionDateStruct":637,"leadSponsor":639,"locationsCount":46},"100287719","tdcs-on-parkinsons-disease-cognition-100287719","NCT03025334","tDCS on Parkinson's Disease Cognition","Transcranial Direct Current Stimulation Treatment of Cognitive Dysfunction in Parkinson's Disease","tDCS-PD-fMRI","Inclusion Criteria:\n\n* Patients must meet diagnostic criteria for idiopathic Parkinson's disease, defined as the presence of two or more of the cardinal clinical features of PD in the absence of known causes of parkinsonism such as encephalitis or neuroleptic treatment\n* Ability to provide written informed consent\n* defined by the Diagnostic and Statistical Manual of Mental Disorders; DSM-5)\n* Age \\> 40\n* fluent in English.\n* Patients' cognitive statuses will be evaluated by the participating neuropsychiatrist or a trained psychiatry or neurology resident.\n\nExclusion Criteria:\n\n* Patients with dementia (defined as a Montreal Cognitive Assessment score \\\u003C 18)\n* Atypical parkinsonian features including myoclonus, apraxia, oculomotor abnormalities, ataxia, sensory loss, or pyramidal signs.\n* Abnormal MRI\n* metal implants or a cardiac pacemaker\n* Pregnant or breastfeeding women (female subjects of child bearing potential will be screened for pregnancy before MRI imaging).\n* severe dyskinesia that may interfere with the quality of the scan (e.g., dyskinesia involving head movement).\n* severe hypertension.\n* cardiovascular disease.\n* Patients with a history of seizure, stroke, moderate to severe head injury, high intracranial pressure, severe headaches, or presence of other neurologic disease that may be associated with an altered seizure threshold; or concurrent medication use, such as tricyclic antidepressants, neuroleptic medications, or other drugs that are known to lower seizure threshold\n* secondary conditions that may significantly alter electrolyte balance or lower seizure threshold.\n* Family history of epilepsy.","40 Years",{"count":628,"type":22},36,[25],"Parkinson's disease (PD) has been classically regarded as a \"movement disorder\", so earlier work has focused on treating motor symptoms only. As PD patients now have longer life expectancy, the relatively slowly progressing cognitive deficits (compared to their motor deficits) have become one of the major challenges. Approximately 80% of PD patients eventually become demented. Therefore cognitive dysfunction is one of the most significant factors affecting the quality of life of patients with PD. While dementia in Parkinson's disease is routinely treated by cholinesterase inhibitors (e.g., donepezil and rivastigmine), their efficacy on mild cognitive impairment found in non-demented PD is questionable. Alternative approaches have been proposed including transcranial direct current stimulation (tDCS) but no consensus has been reached. This can be attributed mainly to: (1) imprecise knowledge of the underlying functional circuitry mediating this disease manifestation and (2) inter-individual variability. Here, the investigators will utilize a novel personalized network analysis approach to elucidate on the underlying mechanisms of the effect of tDCS on cognitive dysfunction in non-demented PD patients.\n\nIt has been well documented that the caudate nucleus plays an important role in cognitive dysfunction found in PD. In the investigators' preliminary resting-state functional magnetic resonance imaging (fMRI) study, they have shown that the connectivity of the right caudate nucleus is correlated to cognitive status of PD patients measured by the Montreal Cognitive Assessment (MoCA). The investigators hypothesize that tDCS on the left and\u002For right dorsolateral prefrontal cortex may restore the functional connectivity of the right caudate nucleus which may in turn improve patients' cognitive performance.",[632,633],"Parkinson Disease","Mild Cognitive Impairment",{"date":613,"type":38},{"date":636,"type":38},"2017-03-22",{"date":638,"type":22},"2027-08-31",{"name":44,"class":45},""]